Taiwan's Food and Drug Administration said it will start a safety reassessment of GLP-1 weight-loss injectables after the U.S. FDA required makers to add a warning on rare optic neuropathy, which may raise the risk of blindness.
Today's highlights
🌏 Regional Digest
🏷️ Topic Digest
🗞️ Latest news by region
Loading...
